A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
Status:
Recruiting
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This is a Phase 3, randomized, open-label, multicenter, study in male and female pediatric
subjects (2 years to <18 years of age) with IDA, or felt by their clinician to be at risk of
developing IDA. This study allows for enrollment of subjects with IDA regardless of etiology,
except for CKD subjects (pediatric CKD subjects are being studied in a separate ferumoxytol
protocol).
Phase:
Phase 3
Details
Lead Sponsor:
AMAG Pharmaceuticals, Inc.
Treatments:
Ferric Oxide, Saccharated Ferrosoferric Oxide Iron